SCHEMBL6300884

SCHEMBL6300884

CO[Si](CCCN(CCN)CCO)(OC)OC

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL291935 0.91 LCK (0.38) LCK
SCHEMBL1070735 0.91 LMNA (0.33)
SCHEMBL495659 0.91 LMNA (0.33)
SCHEMBL337730 0.91 LCK (0.38) LCK
SCHEMBL17272690 0.89 LMNA (0.32)
SCHEMBL964926 0.89 LMNA (0.32)
SCHEMBL12190565 0.87 LCK (0.35) LCK
Acetic Acid SCHEMBL9438154 0.84 LCK (0.32) LCK
SCHEMBL12190478 0.84 LCK (0.37) LCK
SCHEMBL1070750 0.84 LMNA (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117801178-A Polycarboxylic acid water reducer and preparation process thereof 浙江五龙新材股份有限公司 2024-04-02 CN claimed
CN-117801178-A Polycarboxylic acid water reducer and preparation process thereof 浙江五龙新材股份有限公司 2024-04-02 CN disclosed
CN-111250065-A Preparation method and application of EDTA (ethylene diamine tetraacetic acid) modified mussel shell powder 浙江海洋大学 2020-06-09 CN disclosed
US-8029577-B2 Lightening and/or dyeing of human keratin fibres via a composition comprising a particular amino silicon compound and composition and device L'OREAL S.A. (FR) 2011-10-04 US disclosed
US-7909889-B2 Lightening and/or coloring human keratin fibers using at least one aminotrialkoxy silane or at least one aminotrialkenyloxy silane composition L'OREAL S.A. (FR) 2011-03-22 US disclosed
US-7905927-B2 Method for lightening and/or coloring human keratin fibers using a composition comprising an aminotrialkoxy silane or aminotrialkenyloxy silane compound and device L'OREAL, SA (FR) 2011-03-15 US disclosed
US-20100303748-A1 METHOD FOR LIGHTENING AND/OR COLORING HUMAN KERATIN FIBERS USING A COMPOSITION COMPRISING AN AMINOTRIALKOXY SILANE OR AMINOTRIALKENYLOXY SILANE COMPOUND AND DEVICE L'OREAL S.A. (FR) 2010-12-02 US disclosed
US-20100297049-A1 LIGHTENING AND/OR DYEING OF HUMAN KERATIN FIBRES BY MEANS OF A COMPOSITION COMPRISING A PARTICULAR AMINO SILICON COMPOUND AND COMPOSITION AND DEVICE L'OREAL S.A. (FR) 2010-11-25 US disclosed
US-20100275387-A1 LIGHTENING AND/OR COLORING HUMAN KERATIN FIBERS USING AT LEAST ONE AMINOTRIALKOXY SILANE OR AT LEAST ONE AMINOTRIALKENYLOXY SILANE COMPOSITION L'OREAL S.A. (FR) 2010-11-04 US disclosed
US-6979543-B2 Method for detecting biological agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-12-27 US disclosed
US-20040023272-A1 Method for detecting biological agents LOS ALAMOS NATIONAL SECURITY, LLC 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303748-A1 METHOD FOR LIGHTENING AND/OR COLORING HUMAN KERATIN FIBERS USING A COMPOSITION COMPRISING AN AMINOTRIALKOXY SILANE OR AMINOTRIALKENYLOXY SILANE COMPOUND AND DEVICE KRT18, FABP4, APMAP LCK 1292/4885
US-20100275387-A1 LIGHTENING AND/OR COLORING HUMAN KERATIN FIBERS USING AT LEAST ONE AMINOTRIALKOXY SILANE OR AT LEAST ONE AMINOTRIALKENYLOXY SILANE COMPOSITION KRT18, FABP4, ALDH7A1 LCK 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.